On 16 February it was announced that Stockholm3 is included in the revised national prostate cancer guidelines, which have been submitted for consultation and are expected to be introduced in 2022. Stockholm3 is recommended to be included in the projects for organized prostate cancer testing that are planned in Sweden.
”We are very pleased that the improved precision that Stockholm3 provides contributes to Sweden now evaluating modern tools for early detection of prostate cancer. This is an opportunity to save up to 1,000 lives per year in Sweden alone,” said David Rosén, CEO of A3P Biomedical.
In 2018, the Ministry of Health and Social Affairs commissioned the Regional Cancer Centers to standardize and streamline prostate cancer testing in Sweden and identify complementary diagnostic tests. Revised "National prostate cancer guidelines" have now been submitted for consultation and contain recommendations from the national working group for organized prostate cancer testing (OPT) (1).
The revised guidelines state "that there is solid evidence that Stockholm3 can select men with PSA above a certain level for further investigation and, at the same time, reduce the proportion of men who need to undergo magnetic camera examination" and that "the local OPT projects are well-suited for further clinical evaluation of Stockholm3”. The revised guidelines are planned to be introduced after the consultation round, which ends in May 2022.
(1) Referral round – National prostate cancer guidelines, February 2022